Literature DB >> 25498106

Myelomeningocele: How we can improve the assessment of the most severe form of spina bifida.

George M Smith1, Barbara Krynska2.   

Abstract

Myelomeningocele (MMC) is a devastating spinal cord birth defect, which results in significant life-long disabilities, impaired quality of life, and difficult medical management. The pathological progression of MMC involves failure in neural tube and vertebral arch closure at early gestational ages, followed by subsequent impairment in spinal cord and vertebral growth during fetal development. MMC is irreversible at term. Thus, prenatal therapeutic strategies that interrupt progressive pathological processes offer an appealing approach for treatment of MMC. However, a thorough understanding of pathological progression of MMC is mandatory for appropriate treatment to be rendered. This article is part of a Special Issue entitled SI: Spinal cord injury.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Birth defects; Micro-computed tomography; Myelomeningocele; Spina bifida; Spinal cord injury; Vertebral defects

Mesh:

Year:  2014        PMID: 25498106     DOI: 10.1016/j.brainres.2014.11.053

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Shunt timing in meningomyelocele and clinical results: analysis of 80 cases.

Authors:  İsmail İştemen; Ali Arslan; Semih Kıvanç Olguner; Vedat Açik; Ali İhsan Ökten; Mehmet Babaoğlan
Journal:  Childs Nerv Syst       Date:  2020-07-06       Impact factor: 1.532

2.  In Utero Amniotic Fluid Stem Cell Therapy Protects Against Myelomeningocele via Spinal Cord Coverage and Hepatocyte Growth Factor Secretion.

Authors:  Yushi Abe; Daigo Ochiai; Hirotaka Masuda; Yu Sato; Toshimitsu Otani; Marie Fukutake; Satoru Ikenoue; Kei Miyakoshi; Hideyuki Okano; Mamoru Tanaka
Journal:  Stem Cells Transl Med       Date:  2019-08-13       Impact factor: 6.940

Review 3.  Intelligence Quotient in Patients with Myelomeningocele: A Review.

Authors:  Yusuf Alimi; Joe Iwanaga; Rod J Oskouian; Marios Loukas; R Shane Tubbs
Journal:  Cureus       Date:  2018-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.